Positive Safety Data Propels Clearmind Medicine's CMND-100 to Next Clinical Trial Stage
CMND sits 29% above its 52-week low of $1.05 on light trading volume (0.1× avg).
Summary
Clearmind Medicine Inc. announced that its independent Data and Safety Monitoring Board (DSMB) has approved the progression of its CMND-100 Phase I/IIa clinical trial for Alcohol Use Disorder to the third cohort. This critical approval follows a second interim review, which reinforced positive safety results and a favorable profile for CMND-100, with no serious adverse events reported in the second cohort. This news builds on the company's January 14, 2026 announcement of completing treatment for the second cohort. For a micro-cap clinical-stage biotech, DSMB approval to advance a drug is a significant de-risking event, validating the drug's safety and tolerability and providing a material positive catalyst for the stock. Investors will now watch for updates on the third cohort's progress and further data readouts.
At the time of this announcement, CMND was trading at $1.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $1.05 to $52.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.